Table 3.
The effects of resveratrol (RSV) on serum levels of Fasting blood sugar (FBS), insulin, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
| Groups |
FBS(mg/dL)
|
Insulin
( μU/ml ) |
HOMA-IR | ||
|---|---|---|---|---|---|
| Baseline | 7 th day after diabetes induction | End of treatment | |||
| Cont. | 87.3±10.6 | 89.12±10.7 | 92.0±10.8 | 11.17±1.06 | 2.51±0.37 |
| Dia. | 95.62±7.3 | 279.2±95.3a | 303.3±92.1a | 7.23±1.15a | 5.46±2.09a |
| Dia+RSV1 | 93.2±14.8 | 289.7±79.2a | 271.3±77.5 | 8.13±0.97 | 5.52±1.92 |
| Dia+RSV5 | 84.1±11.0 | 219.3±120a | 192.5±84.8b | 9.52±1.0.5b | 3.73±2.01c |
| Dia+RSV10 | 90.5±7.23 | 241.2±99.8a | 190.3±68.6b | 9.83±0.86b | 4.77±1.08c |
Results are represented as mean ±SD
FBS: Fasting blood sugar; HOMA-IR: Homeostatic Model Assessment of Insulin Resistance. Cont.: Healthy control group, Dia.: diabetic control group, Dia+RSV1, Dia+RSV5, and Dia+RSV10 are diabetic rats treated with doses of 1, 5, and 10mg/kg body weight of RSV, respectively
a: P-value <0.001 compared with the control group (Cont.). b: P-value<0.001 compared with the diabetic group (Dia.). c: P-value<0.05 compared with the diabetic group